Aspire Growth Partners LLC Cytom X Therapeutics, Inc. Transaction History
Aspire Growth Partners LLC
- $102 Billion
- Q4 2024
A detailed history of Aspire Growth Partners LLC transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Aspire Growth Partners LLC holds 40,780 shares of CTMX stock, worth $32,216. This represents 0.04% of its overall portfolio holdings.
Number of Shares
40,780Holding current value
$32,216% of portfolio
0.04%Shares
1 transactions
Others Institutions Holding CTMX
# of Institutions
71Shares Held
46.1MCall Options Held
3.7KPut Options Held
4.7K-
Tang Capital Management LLC San Diego, CA7.31MShares$5.78 Million0.57% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$4.13 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.16MShares$4.08 Million0.0% of portfolio
-
Prosight Management, LP Dallas, TX3.91MShares$3.08 Million1.19% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.22MShares$2.54 Million0.0% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $52.1M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...